Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2021-05-27 Regulatory Filings
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 100% confidence The document text is essentially empty, containing only placeholder lines and an omitted picture reference, with no substantive content or context. It does not contain any financial data, report titles, regulatory references, or any information that would allow classification into a specific filing category. Given the lack of content, the appropriate classification is the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2021-05-27 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short clarification or rejoinder statement regarding ongoing discussions about manufacturing a Covid vaccine. It does not contain financial data, regulatory filings, or detailed corporate governance information. It is not an announcement of voting results, management changes, or financial reports. It is a general regulatory announcement clarifying a news item, fitting best under Regulatory Filings (RNS). The document length is short and it is not a report or presentation.
2021-05-15 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited responding to a query about an increase in trading volume of the company's securities. It clarifies that there is no material information or announcement affecting the price or volume and that the company has complied with disclosure regulations. The document is a regulatory communication clarifying market activity rather than a financial report, earnings release, or other formal filing. It does not contain financial data, management discussion, or report publication. It fits best as a Regulatory Filing (RNS) since it is a compliance-related disclosure responding to a regulatory inquiry.
2021-05-15 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited responding to a query about an increase in trading volume of the company's securities. It clarifies that there is no material information or announcement affecting price/volume and that the company has complied with disclosure regulations. The document is a regulatory communication clarifying market activity rather than a financial report, earnings release, or management discussion. It does not contain financial data or results, nor does it announce a report or voting results. It fits best as a Regulatory Filing (RNS) because it is a compliance-related disclosure responding to a regulatory inquiry.
2021-04-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated 24 April 2021 announcing the launch of a new range of herbal veterinary products by Hester Biosciences Limited. It focuses on product information, market trends, and company commitments. There is no indication of financial data, regulatory filings, shareholder information, or any formal report or announcement related to financial performance or governance. It is a general corporate announcement about product launch, not fitting into any specific financial or regulatory filing categories. The closest relevant category for such a corporate announcement that does not fit other categories is Regulatory Filings (RNS).
2021-04-24 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated 8 April 2021 announcing that Hester has acquired technology from ICAR-IVRI for the production and commercialization of two vaccines. It describes the agreements signed, the technology transfer, and the intended commercial launch timeline. There are no financial statements, regulatory certifications, or detailed financial data. The content focuses on a business update regarding technology acquisition and product development, typical of a Capital/Financing Update or business development announcement. It is not an Annual Report, Earnings Release, or any regulatory filing. Given the nature of the announcement about acquiring technology and future commercialization plans, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so RPA is not suitable. Confidence is high due to clear business update content.
2021-04-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.